Combined treatment with pegylated interferon–α‐2a and dacarbazine in patients with advanced metastatic melanoma

@article{Hauschild2008CombinedTW,
  title={Combined treatment with pegylated interferon–α‐2a and dacarbazine in patients with advanced metastatic melanoma},
  author={A. H. W. Hauschild and Reinhard Dummer and Selma Ugurel and Katharina C K{\"a}hler and F Egberts and Wolfram Fink and Jeannine Both-Skalsky and Barbara Laetsch and Dirk Schadendorf},
  journal={Cancer},
  year={2008},
  volume={113 6},
  pages={1404-11}
}
BACKGROUND Dacarbazine (DTIC) and pegylated interferon (IFN)-alpha-2a have both demonstrated some efficacy as single agents in metastatic melanoma. To the authors' knowledge, the current study is the first to test a combination of these 2 agents in a phase 2 trial. METHODS Twenty-eight patients with stage IV melanoma without brain metastases were treated with DTIC (at a dose of 850 mg/m(2) every 3 weeks) combined with weekly pegylated IFN-alpha-2a at a dose of 180 microg. The study was… CONTINUE READING

Similar Papers

Loading similar papers…